PODD Insulet Corporation

  1. Stocks
  2. Healthcare
  3. NASDAQ: PODD

Price (delayed)

$149.25

Market cap

$10.35B

P/E Ratio

24.31

Dividend/share

N/A

EPS

$6.14

Enterprise value

$10.73B

?
Relative Growth: Rel. Growth: 99
Relative Strength: Rel. Strength: 29
Relative Valuation: Rel. Valuation: 64
Relative Profitability: Rel. Profitability: 95

Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin ...

Highlights
PODD's price to earnings (P/E) is 99% lower than its 5-year quarterly average of 1999.5 and 46% lower than its last 4 quarters average of 44.9
The EPS has soared by 75% YoY and by 15% from the previous quarter
Insulet's quick ratio has decreased by 17% YoY but it has increased by 3.3% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.insulet.com
Peers: ICUI DCTH TNDM DXCM

Key stats

What are the main financial stats of PODD

PODD stock price

How has the Insulet stock price performed over time
Intraday
-0.52%
1 week
-4.4%
1 month
6.75%
1 year
-55.69%
YTD
-47.49%
QTD
14.39%

Financial performance

How have Insulet's revenue and profit performed over time
Revenue
$3.19B
Gross profit
$2.29B
Operating income
$587.9M
Net income
$428.8M
Gross margin
71.9%
Net margin
13.4%
PODD's net income has surged by 74% year-on-year and by 14% since the previous quarter
The company's net margin rose by 37% YoY and by 9% QoQ
Insulet's operating income has increased by 35% YoY and by 14% QoQ
PODD's gross profit is up by 27% YoY and by 6% from the previous quarter

Price vs fundamentals

How does PODD's price correlate with its fundamentals

Growth

What is Insulet's growth rate over time

Valuation

What is Insulet stock price valuation
PODD P/E details
P/E
24.31
P/B
6.56
P/S
3.25
EV/EBIT
17.64
EV/EBITDA
15.03
EV/Sales
3.36
PODD's price to earnings (P/E) is 99% lower than its 5-year quarterly average of 1999.5 and 46% lower than its last 4 quarters average of 44.9
The EPS has soared by 75% YoY and by 15% from the previous quarter
PODD's price to book (P/B) is 71% less than its 5-year quarterly average of 22.5 and 30% less than its last 4 quarters average of 9.4
The equity is up by 14% YoY and by 11% QoQ
PODD's price to sales (P/S) is 67% lower than its 5-year quarterly average of 9.8 and 31% lower than its last 4 quarters average of 4.7
PODD's revenue is up by 26% year-on-year and by 4.4% since the previous quarter

Efficiency

How efficient is Insulet business performance
The return on assets has surged by 79% year-on-year and by 11% since the previous quarter
Insulet's return on invested capital has surged by 75% YoY and by 7% QoQ
PODD's ROE has soared by 61% YoY and by 10% QoQ
The ROS has grown by 33% YoY and by 6% from the previous quarter

Dividends

What is PODD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PODD.

Financial health

How did Insulet financials performed over time
The total assets is 86% higher than the total liabilities
Insulet's quick ratio has decreased by 17% YoY but it has increased by 3.3% from the previous quarter
The current ratio has decreased by 13% YoY
The company's debt is 39% lower than its equity
The debt to equity has decreased by 16% YoY and by 9% from the previous quarter
The equity is up by 14% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.